One of the worst things that we can do for our wealth is sell the best ASX growth shares. Businesses that are winners tend to keep winning. It's rare to find companies that have strong economic moats, but it's a good idea to stay invested in those rare breeds for the long-term.
Not only would you be triggering a capital gains tax event, but there's a fair chance you'll end up investing in a business that isn't as good.
These are three ASX growth shares I don't think you should ever sell:
Altium Limited (ASX: ALU)
I've made the mistake of selling some Altium shares in the past. I sold some of my position and then bought a smaller number of shares for a lower price, but I wish I hadn't sold any because the share price has gone up a lot since then.
Altium is one of the most exciting businesses on the ASX with its services being partly responsible for enabling the creation of many of today's devices, vehicles and machines which are changing the world we live in to become a more technological world.
A diversified product range, excellent management, growing profit margins, no debt and rising dividends – there's a lot to like about Altium. It's predicting strong growth for at least the next five years.
REA Group Limited (ASX: REA)
I think REA Group is the best way to profit from the Aussie live of property. It takes a portion of a property seller's advertising budget every time something is listed on realestate.com.au. It's the clear market leader and it would be a big mistake by sellers not to use REA Group's service.
The brand power means it can steadily raise prices with little detrimental effect. That's a sign of a great business position.
Even when the Australian property market was struggling it was benefiting because properties had to be listed longer online.
REA Group has investments in property websites in Asia and North America that could be good profit centres over the long-term.
CSL Limited (ASX: CSL)
CSL has proven to be one of the most high-quality businesses on the ASX. It has carved out a position as a world-leading healthcare giant with excellent research & development capabilities and market-leading products.
It would have been a mistake to sell CSL throughout the 2010s and I think it could be a mistake to sell CSL in the 2020s too as its profit grows and dividend payouts continue to rise.
CSL itself invests in its future products for the long-term, which is why I think CSL is a good long-term idea, though I'd only buy a small amount at the current prices.
Foolish takeaway
You can't go too wrong if you fill your portfolio with high-quality ASX growth shares like the above names for the long-term and don't sell.
